A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis‐Related Safety Signals

Documenti analoghi

• A Real‐World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
  di: Le Hai, et al.
  Pubblicazione: (2024)
• A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
  di: Le Hai, et al.
  Pubblicazione: (2025)
• Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System ( FAERS ) Database
  di: Zhenpo Zhang, et al.
  Pubblicazione: (2025)
• Aioli: Standardising Drugs in the FDA Adverse Event Reporting System ( FAERS ) to RxNorm and Anatomical Therapeutic Chemical ( ATC ) Codes
  di: Rowan E. Parry, et al.
  Pubblicazione: (2025)
• Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
  di: William Bai, et al.
  Pubblicazione: (2025)